Pharmaceutical

China’s NMPA approves Antengene’s XPOVIO for DLBCL

China's NMPA approved Antengene’s new indication of XPOVIO for adults with relapsed or refractory diffuse large B-cell lymphoma.

Jul 10, 2024 - 04:00
China’s NMPA approves Antengene’s XPOVIO for DLBCL
China's NMPA approved Antengene’s new indication of XPOVIO for adults with relapsed or refractory diffuse large B-cell lymphoma.
Read the original article

Tags:

Previous Article

UK pharma group reprimands Novo Nordisk for undisclosed payments

Next Article

Mesoblast Resubmits BLA For Ryoncil Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Gain-of-function research is about much more than dangerous pathogens

Opinion: Gain-of-function research is about much more t...

Jul 22, 2023

STAT+: Leaked version of EFTA-India free trade deal sparks alarm over access to medicines

STAT+: Leaked version of EFTA-India free trade deal spa...

Feb 15, 2024

Galecto terminates development for its lead candidate

Galecto terminates development for its lead candidate

Aug 16, 2023